A mechanistic approach to antiepileptic drug interactions

OBJECTIVE: To describe the primary types of antiepileptic drug (AED) interactions by using a mechanistic approach. DATA SOURCES: A literature search was performed using MEDLINE and bibliographies of recent review articles and published abstracts. DISCUSSION: AEDs are associated with a wide range of drug interactions, including hepatic enzyme induction and inhibition and protein-binding displacement. Hepatic induction by AEDs affects the metabolism of a limited number of drugs with low therapeutic indices. Anticipation of induction interactions and careful clinical monitoring may alleviate potential problems. Most commonly used AEDs are eliminated through hepatic metabolism catalyzed by the cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes. Phenytoin, phenobarbital, and carbamazepine induce CYP and UGT enzymes. Lamotrigine is a weak inducer of UGT. Valproate is a broad-spectrum inhibitor of UGT enzymes, epoxide hydrolase, and CYP2C enzymes. Felbamate induces CYP3A4, but inhibits CYP2C19 substrates. Topiramate inhibits only CYP2C19 substrates. Ethosuximide, gabapentin, tiagabine, and vigabatrin are neither inducers nor inhibitors of drug metabolism. Hepatic enzyme inhibition usually occurs because of competition at the enzyme site. Knowledge of the specific metabolic enzymes involved in the metabolism of AEDs allows clinicians to predict potential interactions. CONCLUSIONS: By understanding the mechanisms of drug interactions, the pharmacist can play a key role in patient care by anticipating and preventing AED drug interactions.

This article has been cited by other articles:

				M. A. Steinman, L. A. Bero, M.-M. Chren, and C. S. Landefeld Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents Ann Intern Med, August 15, 2006; 145(4): 284 - 293. [Abstract] [Full Text] [PDF]

				N. Dragin, T. P. Dalton, M. L. Miller, H. G. Shertzer, and D. W. Nebert For Dioxin-induced Birth Defects, Mouse or Human CYP1A2 in Maternal Liver Protects whereas Mouse CYP1A1 and CYP1B1 Are Inconsequential J. Biol. Chem., July 7, 2006; 281(27): 18591 - 18600. [Abstract] [Full Text] [PDF]

				T. Shimizu, K. Akimoto, T. Yoshimura, T. Niwa, K. Kobayashi, M. Tsunoo, and K. Chiba AUTOINDUCTION OF MKC-963 [(R)-1-(1-CYCLOHEXYLETHYLAMINO)-4-PHENYLPHTHALAZINE] METABOLISM IN HEALTHY VOLUNTEERS AND ITS RETROSPECTIVE EVALUATION USING PRIMARY HUMAN HEPATOCYTES AND CDNA-EXPRESSED ENZYMES Drug Metab. Dispos., June 1, 2006; 34(6): 950 - 954. [Abstract] [Full Text] [PDF]

				D. E Bates and R. J Herman Carbamazepine Toxicity Induced by Lopinavir/Ritonavir and Nelfinavir Ann. Pharmacother., June 1, 2006; 40(6): 1190 - 1195. [Abstract] [Full Text] [PDF]

				W. R Garnett Optimizing Antiepileptic Drug Therapy in the Elderly Ann. Pharmacother., November 1, 2005; 39(11): 1852 - 1860. [Abstract] [Full Text] [PDF]

				N. B. Sandson, S. C. Armstrong, and K. L. Cozza An Overview of Psychotropic Drug-Drug Interactions Psychosomatics, October 1, 2005; 46(5): 464 - 494. [Abstract] [Full Text] [PDF]

				J. de Leon, S. C. Armstrong, and K. L. Cozza The Dosing of Atypical Antipsychotics Psychosomatics, June 1, 2005; 46(3): 262 - 273. [Abstract] [Full Text] [PDF]

				F. J. Coves-Orts, J. Borras-Blasco, A. Navarro-Ruiz, A. Murcia-Lopez, and F. Palacios-Ortega Acute Seizures Due to a Probable Interaction Between Valproic Acid and Meropenem Ann. Pharmacother., March 1, 2005; 39(3): 533 - 537. [Abstract] [Full Text] [PDF]

				A. Richard, F. Girard, D. C. Girard, D. Boudreault, P. Chouinard, R. Moumdjian, A. Bouthilier, M. Ruel, J. Couture, and F. Varin Cisatracurium-Induced Neuromuscular Blockade Is Affected by Chronic Phenytoin or Carbamazepine Treatment in Neurosurgical Patients Anesth. Analg., February 1, 2005; 100(2): 538 - 544. [Abstract] [Full Text] [PDF]

				L. Citrome, R. Josiassen, N. Bark, D. E. Salazar, and S. Mallikaarjun Pharmacokinetics of Aripiprazole and Concomitant Lithium and Valproate J. Clin. Pharmacol., January 1, 2005; 45(1): 89 - 93. [Abstract] [Full Text] [PDF]

				R. DiCenzo, D. Peterson, K. Cruttenden, G. Morse, G. Riggs, H. Gelbard, and G. Schifitto Effects of Valproic Acid Coadministration on Plasma Efavirenz and Lopinavir Concentrations in Human Immunodeficiency Virus-Infected Adults Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4328 - 4331. [Abstract] [Full Text] [PDF]

				A. R. Tan, X. Yang, S. M. Hewitt, A. Berman, E. R. Lepper, A. Sparreboom, A. L. Parr, W. D. Figg, C. Chow, S. M. Steinberg, et al. Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor J. Clin. Oncol., August 1, 2004; 22(15): 3080 - 3090. [Abstract] [Full Text] [PDF]

				J. de Leon Psychopharmacology: Atypical Antipsychotic Dosing: The Effect of Co-medication With Anticonvulsants Psychiatr Serv, February 1, 2004; 55(2): 125 - 128. [Full Text] [PDF]

				S. C. Armstrong, K. L. Cozza, and N. B. Sandson Six Patterns of Drug-Drug Interactions Psychosomatics, June 1, 2003; 44(3): 255 - 258. [Abstract] [Full Text] [PDF]

				A. Murphy and K. Wilbur Phenytoin-Diazepam Interaction Ann. Pharmacother., May 1, 2003; 37(5): 659 - 663. [Abstract] [Full Text] [PDF]

				H. Joffe, A. E. Taylor, and J. E. Hall EDITORIAL: Polycystic Ovarian Syndrome--Relationship to Epilepsy and Antiepileptic Drug Therapy J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 2946 - 2949. [Full Text] [PDF]

				M. Burt, D. C. Anderson, J. Kloss, and F. S. Apple Evidence-based Implementation of Free Phenytoin Therapeutic Drug Monitoring Clin. Chem., August 1, 2000; 46(8): 1132 - 1135. [Abstract] [Full Text] [PDF]

				T. Suzuki, T. Nakamura, S. Saeki, and S. Ogawa Vecuronium-Induced Neuromuscular Blockade in a Patient with Cerebral Palsy and Hemiplegia Anesth. Analg., August 1, 2000; 91(2): 492 - 493. [Abstract] [Full Text] [PDF]